Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T12:43:49.741Z Has data issue: false hasContentIssue false
  • English
  • Français

The “Pink Spot” in Schizophrenics and its Absence in Homocystinurics

Published online by Cambridge University Press:  29 January 2018

J. Philip Welch ,
Courtney G. Clower  and
R. Neil Schimke
J. Philip Welch
Affiliation:
Division of Medical Genetics, Johns Hopkins Hospital, Baltimore, Maryland 21205
Courtney G. Clower
Affiliation:
Johns Hopkins Hospital, Spring Grove State Hospital, Catonsville, Maryland 21228
R. Neil Schimke
Affiliation:
Division of Medical Genetics, Johns Hopkins Hospital, Baltimore, Maryland 21205
Get access Rights & Permissions [Opens in a new window]

Extract

In 1952 Osmond and Smythies, with Harley-Mason, suggested that schizophrenia might be due to an abnormality in the metabolism of epinephrine, by which a mescaline-like substance such as dimethoxyphenylethylamine (DMPE) might be produced by O-methylation at the third and fourth positions. It was felt then that DMPE might have “psychotomimetic properties” similar to mescaline.

Type
Studies in Schizophrenia
Information
The British Journal of Psychiatry , Volume 115 , Issue 519 , February 1969 , pp. 163 - 167
Copyright
Copyright © Royal College of Psychiatrists, 1969 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barbeau, A., DeGroot, J-A., Joly, J. G., Raymond-Tremblay, D., and Donaldson, J. (1963). “Urinary excretion of a 3,4-dimethoxyphenylethylamine-like substance in Parkinson's disease.” Rev. Can. Biol., 22, 469–472.Google Scholar
Bell, C. E., and Somerville, A. R. (1966). “Identity of the ‘pink spot’.” Nature, 211, 1405–1406.Google Scholar
Bergen, J. R. (1965). “Possible relationship of a plasma factor to schizophrenia.” Trans. N York Acad. Sex., 28, 40–46.Google Scholar
Boulton, A. A., and Felton, G. A. (1966a). “The pink spot: a red herring?” Lancet, 2, 964–965.Google Scholar
Boulton, A. A., and Felton, G. A. Boulton, A. A., and Felton, G. A. (1966b). “The ‘pink spot’ and schizophrenia.” Nature, 211, 1404–1405.CrossRefGoogle Scholar
Boulton, A. A., Pollitt, R. J., and Majer, J. R. (1967). “Identity of a urinary ‘pink spot’ in schizophrenia and Parkinson's disease.” Nature, 215, 132–134.Google Scholar
Bourdillon, R. E., Clarke, G. A., Ridges, A. P., Sheppard, P. M., Harper, P., and Leslie, S. A. (1965). “‘Pink Spot’ in the urine of schizophrenics. Nature, 208, 453–455.Google Scholar
Carson, N. A. J., Cusworth, D. C., Dent, C. E., Field, G. M. B., Neill, D. W., and Westall, R. G. (1963). “Homocystinuria : a new inborn error of metabolism associated with mental deficiency.” Arch. Dis. Childh., 38, 425–436.Google Scholar
Creveling, C. R., and Daly, J. W. (1967). “Identification of 3,4-dimethoxyphenylethylamine from schizophrenic urine by mass spectrometry.” Nature, 216, 190–191.CrossRefGoogle Scholar
Faurbye, A., and Pind, K. (1964). “Investigation of the occurrence of the dopamine metabolite 3,4-dimethoxyphenylethylamine in the urine of schizophrenics. Acta psychiat. Scand., 40, 240–243.Google Scholar
Faurbye, A., and Pind, K. (1966). “Failure to detect 3,4-dimethoxy-phenylethylaminc in the urine of psychotic children. Acta psychiat. Scand. Suppl., 191, 136–148.Google Scholar
Friedhoff, A. J. (1966). “The pink spot: a red herring?” Lancet, 2, 1188.CrossRefGoogle Scholar
Friedhoff, A. J. and Van Winkle, E. (1962a). “Isolation and characterization of a compound from the urine of schizophrenics.” Nature, 194, 897–898.Google Scholar
Friedhoff, A. J., and Van Winkle, E. (1962b). “The characteristics of an amine found in the urine of schizophrenic patients.” J. nerv. ment. Dis., 135, 550–555.Google Scholar
Friedhoff, A. J., and Van Winkle, E. (1963). “A method for the detection of β-phenylethylamines and β-phenylethylarnino-acids.” J. Chromatog., 11, 272–274.Google Scholar
Kety, S. S. (1967). Discussion comment in Amines and Schizophrenia (ed. Himwich, H. E., Kety, S. S. and Smythies, J. R.), 129, 131. Pergamon Press, New York.Google Scholar
Kuehl, F. A. Jun., Hichens, M., Ormond, R. E., Mebinger, M. A. P., Gale, P. H., Girillo, V. J., and Brink, N. G. (1964). “Para-o methylation of dopamine in schizophrenic and normal individuals.” Nature, 203, 154–155.Google Scholar
Kuehl, F. A. Jun., Hichens, M., Ormond, R. E., Mebinger, M. A. P., Gale, P. H., Girillo, V. J., Ormand, R. E. and Van Den Leuvel, W. J. A. (1966). “Occurrence of 3,4-dimethoxyphenylacetic acid in urines of normal and schizophrenic individuals.” Nature, 211, 606–608.CrossRefGoogle Scholar
Nauohton, M. A., and Hagopian, H. (1962). “Some applications of two-dimensional ionophoresis.” Analyt. Biochem., 3, 276–284.CrossRefGoogle Scholar
Osmond, H., and Smythies, J. R. (1952). “Schizophrenia: a new approach.” J. Ment. Sci., 98, 309–315.Google Scholar
Park, L. C., Baldessarini, R. J., and Kety, S. S. (1965). “Methionine effects on chronic schizophrenics.” Arch. gen. Psychiat., 12, 346–351.CrossRefGoogle Scholar
Perry, T. L. (1963). “N-Methylmetanephrine excretion by juvenile psychotics.” Science, 139, 587–589.CrossRefGoogle Scholar
Perry, T. L. (1967). Discussion comment in Amines and Schizophrenia. (Eds. Himwich, H. E., Kety, S. S. and Smythies, J. R.), 265, Pergamon Press, New York.Google Scholar
Perry, T. L., Hansen, S., and MacDougall, L. (1967). “Identity and significance of some pink spots in schizophrenia and other conditions.” Nature, 214, 484–485.CrossRefGoogle Scholar
Perry, T. L., Hansen, S., and MacIntyre, L. (1964). “Failure to detect 3,4-dimethoxyphenylethylamine in the urine of schizophrenics.” Nature, 202, 519–520.CrossRefGoogle Scholar
Perry, T. L., Hansen, S., MacDouoall, L., and Schwarz, C. J. (1966). “Urinary amines in chronic schizophrenia.” Nature, 212, 146–148.CrossRefGoogle Scholar
Pind, K., and Faurbye, A. (1966). “Does 3,4-dimethoxyphenylethylamine occur in the urine from schizophrenics and normal persons?” Acta psychiat. Scand., 42, 246–251.CrossRefGoogle Scholar
Pollin, W., Cardon, P. V. Jun., and Kety, S. S. (1961). “Effects of amino acid feedings in schizophrenic patients treated with iproniazid.” Science, 133, 104–105.CrossRefGoogle Scholar
Sen, N. P., and McGeer, P. L. (1964). “4-methoxyphenylethylamine and 3,4-dimethoxyphenylethylamine in human urine.” Biochem. and biophys. Research Commun., 14, 227–232.Google Scholar
Shulgin, A. T., Sargent, T., and Naranjo, C. (1966). “Role of 3,4-dimethoxyphenylethylamine in schizophrenia.” Nature, 212, 1606–1607.Google Scholar
Smythies, J. R., and Sykes, E. A. (1966). “Structureactivity relationship studies on mescaline: the effect of dimethoxyphenylethylamine and N:N-dimethylmescaline on the conditioned avoidance response in the rat.” Psychopharmacologia (Berl.), 8, 324–330.CrossRefGoogle Scholar
Spiro, H. R., Schimke, R. N., and Welch, J. P. (1965). “Schizophrenia in a patient with a defect in methionine metabolism.” J. nerv. ment. Dis., 141, 285–290.Google Scholar
Takesada, M., Kakimoto, Y., Sano, I., Kaneko, Z. (1963). “3,4-dimethoxyphenylethylamine and other amines in the urine of schizophrenic patients”. Nature, 199, 203–204.Google Scholar
Welch, J. P., and Glower, C. G. (1968). “3,4-dimethoxyphenylethylamine and schizophrenia.” To be published.Google Scholar
Williams, C. H., Gibson, J. G., McGormick, W. O. (1966): “3,4-dimethoxyphenylethylamine in schizophrenia.” Nature, 211, 1195.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.